Loading...
XNASBMRA
Market cap5mUSD
Dec 26, Last price  
0.33USD
1D
16.91%
1Q
3.17%
Jan 2017
-85.87%
Name

Biomerica Inc

Chart & Performance

D1W1MN
XNAS:BMRA chart
P/E
—
P/S
1.01
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
12.80%
Rev. gr., 5y
0.81%
Revenues
5m
+1.42%
9,273,9807,184,9925,748,3194,926,5054,934,7715,075,2224,899,3756,081,1316,472,9605,120,4514,962,3735,139,8165,791,6705,564,1855,200,6826,692,7117,199,02718,871,4095,339,0005,415,000
Net income
-6m
L-16.27%
162,259230,273536,8791,710,044354,180-331,455157,447548,435536,957-215,660-331,410-1,499,787-908,561-1,465,828-2,393,060-2,339,054-6,469,036-4,531,044-7,140,000-5,978,000
CFO
-5m
L-2.06%
72,920-385,169463,708-194,595-101,999-236,980328,803147,4121,394,037-862,273-405,481-208,782-722,858-1,174,217-2,244,039-4,297,498-5,251,748-480,532-5,474,000-5,361,000
Earnings
Jan 14, 2025

Profile

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
URL
https://biomerica.com/
IPO date
Mar 17, 1980
Employees
62
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑052023‑052022‑052021‑052020‑052019‑052018‑052017‑052016‑052015‑05
Income
Revenues
5,415
1.42%
5,339
-71.71%
18,871
162.14%
Cost of revenue
6,295
6,477
17,706
Unusual Expense (Income)
NOPBT
(880)
(1,138)
1,165
NOPBT Margin
6.17%
Operating Taxes
42
51
24
Tax Rate
2.04%
NOPAT
(922)
(1,189)
1,141
Net income
(5,978)
-16.27%
(7,140)
57.58%
(4,531)
-29.96%
Dividends
Dividend yield
Proceeds from repurchase of equity
(81)
9,309
2,317
BB yield
0.83%
-48.01%
-5.22%
Debt
Debt current
326
297
341
Long-term debt
1,244
1,867
2,418
Deferred revenue
Other long-term liabilities
Net debt
(2,765)
(7,720)
(3,323)
Cash flow
Cash from operating activities
(5,361)
(5,474)
(481)
CAPEX
(51)
(78)
(170)
Cash from investing activities
(115)
(78)
(170)
Cash from financing activities
(81)
9,390
2,395
FCF
(870)
(831)
3,658
Balance
Cash
4,170
9,719
5,917
Long term investments
165
165
165
Excess cash
4,064
9,617
5,139
Stockholders' equity
(46,951)
(40,981)
(34,122)
Invested Capital
54,327
53,787
43,826
ROIC
2.78%
ROCE
12.00%
EV
Common stock shares outstanding
16,822
14,154
12,673
Price
0.58
-57.62%
1.37
-60.86%
3.50
-4.11%
Market cap
9,767
-49.63%
19,391
-56.28%
44,356
1.87%
EV
7,002
11,671
41,033
EBITDA
(506)
(787)
1,760
EV/EBITDA
23.32
Interest
27
Interest/NOPBT
2.29%